FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176756475> ?p ?o ?g. }

• W3176756475 startingPage "8" @default.
• W3176756475 abstract "In 2010, the prevalence of obesity in the United State was 36% among adults (76.3 million overweight and 89.4 million obese) and 17% among children and adolescents. For past 2 decades, obesity has increased globally reaching epidemic levels. Obesity is directly associated with metabolic diseases such as type-2 diabetes and other disorders like hypertension, dyslipidemia, coronary heart disease, stroke, osteoarthritis, depression and sleep apnea. Lifestyle management including healthy diet and increased physical activity is the fundamental approach to treat obesity. Clinical studies have shown that weight loss of 5-10% of initial body weight is sufficient to achieve medical benefits such as reduction of diabetes incidents and cardiovascular risks. However, achieving and maintaining a weight loss is difficult. More than 60% of adults fail to sustain 5% weight loss over the year and regain body weight. Therefore, pharmacological approach as adjunctive therapy to lifestyle change has been developed recently. The 2013 Guideline for Management of Obesity (USA) recommended consideration of pharmacological treatment for obese adults with BMI ≥30 kg/m2 and for overweight adults with BMI ≥27.0 kg/m2 when accompanied by comorbidities such as type-2 diabetes, hypertension or dyslipidemia. The current anti-obesity drugs reduce food intake by suppressing appetite, decrease absorption of fat or increase energy expenditure. FDA criteria to approve antiobesity drugs is a decrease in body weight ≥5% after 1 year of treatment compared to placebo control or if at least 35% of study participants lose ≥5% of their baseline body weight. Weight loss medication should result in significant improvements in blood pressure, lipids, glycaemia or other metabolic conditions. 5 medications for weight management have been approved in the USA (4 of them since 2012): Orlistat (Xenical, Alli), Lorcaserin (Belviq), Phentermine/Topiramate (Qsymia), Naltrexone/ Bupropion (Contrave) and Liraglutade (Saxenda). Pharmacological monotherapies primarily focus on a single protein target or pathway, whereas combination therapy approach appears to provide greater benefit. The Phentermine/Topiramate resulted in the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss. Lorcaserin showed the best tolerability and lowest rate of adverse events. The development of safe and effective weight loss drugs is still important. Preclinical studies have been completed for several therapeutic candidates and now they are under clinical investigation. Thus, additional novel drugs for weight loss are likely to come to the market in the next five years." @default.
• W3176756475 created "2021-07-05" @default.
• W3176756475 creator A5017357591 @default.
• W3176756475 date "2021-01-01" @default.
• W3176756475 modified "2023-09-23" @default.
• W3176756475 title "Biochemistry 2018: Pharmacological treatment of obesity" @default.
• W3176756475 hasPublicationYear "2021" @default.
• W3176756475 type Work @default.
• W3176756475 sameAs 3176756475 @default.
• W3176756475 citedByCount "0" @default.
• W3176756475 crossrefType "journal-article" @default.
• W3176756475 hasAuthorship W3176756475A5017357591 @default.
• W3176756475 hasConcept C126322002 @default.
• W3176756475 hasConcept C134018914 @default.
• W3176756475 hasConcept C1862650 @default.
• W3176756475 hasConcept C2777180221 @default.
• W3176756475 hasConcept C2777646958 @default.
• W3176756475 hasConcept C2778096610 @default.
• W3176756475 hasConcept C2779952866 @default.
• W3176756475 hasConcept C2780586474 @default.
• W3176756475 hasConcept C2780780548 @default.
• W3176756475 hasConcept C34320749 @default.
• W3176756475 hasConcept C511355011 @default.
• W3176756475 hasConcept C544821477 @default.
• W3176756475 hasConcept C555293320 @default.
• W3176756475 hasConcept C71924100 @default.
• W3176756475 hasConceptScore W3176756475C126322002 @default.
• W3176756475 hasConceptScore W3176756475C134018914 @default.
• W3176756475 hasConceptScore W3176756475C1862650 @default.
• W3176756475 hasConceptScore W3176756475C2777180221 @default.
• W3176756475 hasConceptScore W3176756475C2777646958 @default.
• W3176756475 hasConceptScore W3176756475C2778096610 @default.
• W3176756475 hasConceptScore W3176756475C2779952866 @default.
• W3176756475 hasConceptScore W3176756475C2780586474 @default.
• W3176756475 hasConceptScore W3176756475C2780780548 @default.
• W3176756475 hasConceptScore W3176756475C34320749 @default.
• W3176756475 hasConceptScore W3176756475C511355011 @default.
• W3176756475 hasConceptScore W3176756475C544821477 @default.
• W3176756475 hasConceptScore W3176756475C555293320 @default.
• W3176756475 hasConceptScore W3176756475C71924100 @default.
• W3176756475 hasIssue "4" @default.
• W3176756475 hasLocation W31767564751 @default.
• W3176756475 hasOpenAccess W3176756475 @default.
• W3176756475 hasPrimaryLocation W31767564751 @default.
• W3176756475 hasRelatedWork W1594742481 @default.
• W3176756475 hasRelatedWork W1938833282 @default.
• W3176756475 hasRelatedWork W1971830200 @default.
• W3176756475 hasRelatedWork W1982387448 @default.
• W3176756475 hasRelatedWork W1995657140 @default.
• W3176756475 hasRelatedWork W2022046031 @default.
• W3176756475 hasRelatedWork W2028405445 @default.
• W3176756475 hasRelatedWork W2061037446 @default.
• W3176756475 hasRelatedWork W2080193835 @default.
• W3176756475 hasRelatedWork W2117697648 @default.
• W3176756475 hasRelatedWork W2154244655 @default.
• W3176756475 hasRelatedWork W2260747663 @default.
• W3176756475 hasRelatedWork W2303573213 @default.
• W3176756475 hasRelatedWork W2411275859 @default.
• W3176756475 hasRelatedWork W2609075277 @default.
• W3176756475 hasRelatedWork W2626087278 @default.
• W3176756475 hasRelatedWork W2908249173 @default.
• W3176756475 hasRelatedWork W2982833172 @default.
• W3176756475 hasRelatedWork W46209804 @default.
• W3176756475 hasRelatedWork W951114397 @default.
• W3176756475 hasVolume "16" @default.
• W3176756475 isParatext "false" @default.
• W3176756475 isRetracted "false" @default.
• W3176756475 magId "3176756475" @default.
• W3176756475 workType "article" @default.